iZafe Group
3.12.2021 15:02:05 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / December 3, 2021 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) (NASDAQ First North:IZAFE B) hereby announces that the first pharmaceutical robots adapted for the Italian consumer market have now been sent to Sempli Farma in Italy for the pilot project.
In October this year, we communicated the upcoming pilot project in Italy. With a certain delay, we can now announce that the pharmaceutical robots have been sent from Sweden and are expected to be delivered to Sempli Farma next week.
All parts such as Dosell, manuals, mobile app, system and brochure are ready and adapted for the Italian market, which means that Sempli Farma has everything to get started.
About Sempli Farma by Remedio S.R.L
The Italian healthcare company Remedio has built a network of strategically selected partners in Italy to find a combination of different aids in drug management and distribution channels that enable the elderly to stay at home longer. Unlike in Sweden, the possibility of receiving medicine on a dose roll has not existed in Italy; this has inspired Remedio to launch the concept of sachets and develop the complete solution Sempli Farma.
Sempli Farma is a service that connects pharmacists with the patient and their relatives via a pharmacy through a closed system for drug dispensing. The care concept aims to reduce care costs and streamline the Italian healthcare system. Dosell becomes the ultimate end component by delivering the dose bags while at the same time the compliance of the medication can be checked and statistics obtained
Sempli Farma has grown in 2020 and 2021 through a capital raising of
300,000 euros. The organization has been strengthened with a clinical engineer, a sales manager who works to create an external sales network and a marketing and communications department.
Contacts
Carl-Fredrik Bothén, Chief Marketing Officer
E-mail: carl-fredrik.bothen@izafegroup.com
Phone number: +46 73-064 48 67
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm
E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/
About Us
iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.
The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafe.se/investor-relations/.
Attachments
The first Italian version of Dosell was sent today to Sempli Farma in Italy.
SOURCE: iZafe Group
View source version on accesswire.com:
https://www.accesswire.com/675925/The-First-Italian-Version-of-Dosell-was-sent-Today-to-Sempli-Farma-in-Italy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
